Transcatheter aortic valve replacement in patients with systolic heart failure and moderate aortic stenosis (TAVR UNLOAD)

Reported from TCT 2024

Mirvat Alasnag interviews Nicolas M. Van Mieghem about the results of the TAVR UNLOAD trial he presented at the TCT Conference 2024.

TAVR for moderate AS in Heart Failure with reduced Ejection Fraction (HFrEF) patients on GDMT was safe and improved quality of life at one year but didn't affect the primary endpoint at 23 months.
The study faced limitations like slow enrollment, design changes, and higher-than-expected TAVR need in the surveillance group, impacting results.